Immunovant Halted Lupus Drug Trial

The clinical-stage firm ended development of IMVT-1402 after failing to meet the primary endpoint in a recent study.

Updated on Sept. 23, 2026 in Arthritis

Bold flat-color editorial illustration showing a stylized lab centrifuge in navy and cream, representing the halted clinical drug research. — Immunovant has discontinued the clinical development of its lupus drug candidate IMVT-1402 after it failed to meet the primary endpoint in a recent randomized study. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to prioritize patients when deciding to cancel drug development programs?

Immunovant discontinued the clinical development of its drug candidate IMVT-1402 for cutaneous lupus erythematosus. The decision followed a randomized, placebo-controlled trial that failed to reach statistical significance on its primary endpoint.

Why it matters

The company cited both the negative trial results and the broader competitive landscape as reasons for pulling the program. Immunovant intends to shift its focus toward other autoimmune conditions, including rheumatoid arthritis and Graves' disease.

The clinical study enrolled 57 patients for a 12-week treatment period. The trial failed to achieve statistical significance on the CLASI-A percent change metric at Week 12.

The players

Immunovant

Headquartered in Durham, this clinical-stage immunology company is a majority-owned subsidiary of Roivant.

Roivant

This parent organization maintains a majority ownership stake in Immunovant.

The details

Although the drug failed its primary clinical goal, Immunovant noted that IMVT-1402 maintained a safety and tolerability profile consistent with previous studies. Researchers observed that patients who experienced deeper IgG reductions during the trial showed improved clinical outcomes.

September 23, 2026: Immunovant announced the study results.
Week 12: Assessment of the primary endpoint CLASI-A score.

Startups
Sept. 22
Ramona Optics Has Raised $25 Million
Women’s Health
Sept. 21
Duke Researchers Identified Rete Ovarii Functions
Business Strategy
Sept. 24
M&F Bank Rejected Unsolicited Acquisition Proposals

The Big Picture

The discontinuation of this specific program marks a departure from the previously planned therapeutic applications for the IMVT-1402 clinical development program.

Patients currently seeking treatment options for cutaneous lupus erythematosus will not have access to IMVT-1402 via this specific development program. The company remains committed to other autoimmune research that may impact future treatment accessibility for conditions like rheumatoid arthritis.

The takeaway

Clinical trial failures often force companies to reallocate resources toward more promising therapeutic pathways. This shift highlights how manufacturers prioritize assets based on both primary endpoint results and shifting competitive dynamics.